Counsel House
Antitrust & Regulatory

FTC and 13 states sue to block Covetrus' $3.5 billion purchase of Cencora's MWI Animal Health

The agency alleges the deal would merge the two largest US veterinary distributors. Covetrus calls the FTC's market view narrow and outdated and says it will defend the deal.

Covetrus logo. Logo via Wikimedia Commons (CC0)

The Federal Trade Commission and 13 state attorneys general sued on November 13, 2026, to stop Covetrus from acquiring MWI Animal Health. The deal is valued at $3.5 billion. MWI is the veterinary distribution unit of Cencora Inc. Covetrus said the same day that it will defend the transaction in court.

The complaint was filed in the US District Court for the Southern District of New York. It names Covetrus and its private equity owners, Clayton, Dubilier & Rice LLC and TPG Inc. The commission voted 2-0 to authorize staff to seek a permanent injunction.

What the FTC alleges

The FTC alleges that Covetrus and MWI are each other's closest competitors in two markets: distribution to veterinary clinics and distribution to large corporate veterinary accounts. It says the two are the largest suppliers in both. The agency alleges the merger would make those markets highly concentrated and therefore presumptively unlawful under case law and the 2023 merger guidelines issued by the FTC and the Department of Justice. The FTC release reportedly gave no specific market share figures.

The complaint also describes years of price competition. It alleges Covetrus matched MWI's pricing through price cuts and rebates offered through its VetSuite program. It also points to Vetcove, an online platform that lets veterinarians compare prices and use one distributor's offer to negotiate with the other. The complaint calls the result an "all-out price war."

The FTC further contends that specialty distributors, manufacturers and retailers do not meaningfully constrain the major clinic distributors. It alleges new entrants face structural barriers, and that national distribution networks and discounts give the two companies advantages smaller rivals cannot match.

Daniel Guarnera, director of the FTC's Bureau of Competition, said the deal "will reduce competition in an already concentrated market and drive up prices for veterinarians and their customers." These are allegations in a complaint. The court has made no findings.

The deal and the review

Covetrus and Cencora announced the transaction in February 2026. Cencora would receive $1.25 billion in cash, $800 million in preferred equity and $1.45 billion in common equity in the combined company. That would leave it with a 34.3% noncontrolling stake.

The state plaintiffs are Arizona, Arkansas, California, Colorado, Maine, Michigan, Minnesota, Nebraska, New York, North Carolina, Ohio, Oregon and Texas. Bloomberg Law reported the group as 12 states; the count here is 13.

Covetrus' response

Covetrus said the FTC's view of the market is narrow and outdated. It said the lawsuit does not reflect how veterinarians actually buy products. It points to competition from manufacturers selling directly to practices, other distributors and online marketplaces. It also says practices buy from multiple sources and can switch suppliers.

Covetrus said it is "fully prepared to defend" the merger in court. Ben Wolin, Covetrus' president and CEO, said when the deal was announced that it was about making animal health care more affordable and accessible.

What this means for in-house counsel

The case shows how much a market definition fight can matter. The FTC's presumption of illegality depends on the markets the FTC defines for clinic and corporate-account distribution. Covetrus' defense depends on a wider market that includes manufacturer direct sales and online marketplaces. Deal teams should test those alternatives early, using customer switching data and internal documents. Any internal document that calls a counterparty the closest rival can become evidence.

Counsel may want to revisit allocation provisions: outside dates, efforts covenants, and any reverse termination fees or divestiture commitments. They may also want to plan for parallel state action. As a general matter, a federal settlement does not guarantee that state plaintiffs will go along, and 13 attorneys general joined the federal complaint here.

For companies that buy from veterinary distributors, or from any concentrated supply channel, expect agency and state information requests. Preserve documents on pricing, rebates and switching, and check whether supply contracts give you rights if a counterparty merges. Anyone with a view on the competitive effects should expect to be asked for it.

Free weekly email

The Counsel House Brief

The week's most important legal news for general counsel and in-house teams, in one short email.

Counsel House corrects errors promptly. Spot one? Email daniel@counselhouse.org.

← All newsJoin Counsel House →